Mechelen, Belgium and Hannover, Germany; 5 October 2010 - Galapagos NV (Euronext: GLPG) announced that it won the European Biotechnica Award at last night's ceremony in Hannover. Presented each year by the Deutsche Messe, the Biotechnica award recognizes European-based biotechnology companies that have developed particularly innovative products, services and business ideas.
The international jury, which consisted of nine industry experts from five countries, selected Galapagos as the winner of the 2010 award. The prize is presented to European companies that have made a name for themselves in the biotech and life sciences sectors due to their market success and innovative prowess. Galapagos received a cash prize of €30,000 for winning the award.
"We are pleased to have won this year's Biotechnica Award, which recognizes the power of Galapagos' technology platform and its impact on the sector," said Onno van de Stolpe, CEO of Galapagos. "We will continue to work toward achieving our ambition of becoming the leading innovative biotech in Europe."
"Galapagos shows a remarkable combination of scientific know-how in different fields and business success through cooperations with eight big pharma companies," added Prof. Dr. Rolf G. Werner, deputy chair of the international Biotechnica jury panel.
Biotechnica is Europe's leading annual event for biotechnology and the life sciences. It covers the entire spectrum of biotechnology, including fundamentals and equipment, bio-informatics and services, and addresses all five major fields of application, i.e. pharmaceuticals/medicine, industrial manufacturing, food, agriculture and the environment. Since 1985, Biotechnica has been organized and staged by Deutsche Messe AG in Hannover, Germany.
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with six clinical and over 50 small molecule discovery/pre-clinical programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Merck & Co., Roche and Servier, Galapagos is eligible to receive up to €3.3 billion in downstream milestones, plus royalties. Following the acquisition of the Zagreb research center, the Galapagos Group now has over 800 employees and operates facilities in seven countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.